ArticleJournal of materials science. Materials in medicine2022
Hyaluronic acid-coated chitosan nanoparticles as targeted-carrier of tamoxifen against MCF7 and TMX-resistant MCF7 cells.
Article in Journal of materials science. Materials in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 50 citations in OpenAlex.
- A tumor microenvironment-responsive calcium overload nanoplatform inducing PANoptosis for enhanced cancer immunotherapy.Materials today. Bio · 2026Article
- Targeted nanocomposite delivery system of amygdalin using chitosan/reduced graphene oxide-zinc oxide/hyaluronic acid for treatment of head and neck squamous cell carcinoma.BMC oral health · 2026Article
- Cyclodextrin-Based Formulations as a Promising Strategy to Overcome the Blood-Brain Barrier: Historical Overview and Prospects in Glioblastoma Treatment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Natural Polysaccharide-Based Nanoparticles Enhance Intracellular Delivery and Cytotoxicity ofInternational journal of molecular sciences · 2025Article
- Synthesis of Chitosan Nanoparticles via Microfluidic Approach: The Role of Temperature in Tailoring Aggregation for Enhanced Uniformity.Micromachines · 2025Article
- Breaking barriers: Smart vaccine platforms for cancer immunomodulation.Cancer communications (London, England) · 2025Review
- Formulation Development of Natural Polymeric Nanoparticles, In Vitro Antiaging Evaluation, and Metabolite Profiling ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Production and Characterization of Nanoparticulate Polyelectrolyte Complexes of Chitosan-Catechol, Ulvan, and Hyaluronic Acid.ACS omega · 2025Article
- Effect of chitosan nanoparticles loaded with platelet lysate on in vitro fertilization and early embryo development in a mouse premature ovarian failure model.Iranian journal of basic medical sciences · 2025Article
- Biopolymeric Innovations in Ophthalmic Surgery: Enhancing Devices and Drug Delivery Systems.Polymers · 2024Review
- Cytotoxicity Enhancement of α-Mangostin with Folate-Conjugated Chitosan Nanoparticles in MCF-7 Breast Cancer Cells.Molecules (Basel, Switzerland) · 2023Article
- Nanotargeted Delivery of Immune Therapeutics in Type 1 Diabetes.Advanced materials (Deerfield Beach, Fla.) · 2023Article
- Amelioration of Cancer Employing Chitosan, Its Derivatives, and Chitosan-Based Nanoparticles: Recent Updates.Polymers · 2023Review
- Therapeutic applications of nanobiotechnology.Journal of nanobiotechnology · 2023Review
- Chitosan-Based Nano-Smart Drug Delivery System in Breast Cancer Therapy.Pharmaceutics · 2023Review
- Hyaluronic Acid-Coated Chitosan Nanoparticles as an Active Targeted Carrier of Alpha Mangostin for Breast Cancer Cells.Polymers · 2023Article
- Chitosan-Based Nanoparticles with Optimized Parameters for Targeted Delivery of a Specific Anticancer Drug-A Comprehensive Review.Pharmaceutics · 2023Review
- Review
- Green synthesis of hyaluronic acid coated, thiolated chitosan nanoparticles for CD44 targeted delivery and sustained release of Cisplatin in cervical carcinoma.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tamoxifen (TMX) is used to treat hormone-receptor-positive breast cancers at early stages. This research aimed to assess the potential of NPs in targeted delivery of TMX against MCF7 and TMX-resistant MCF7 breast cancer cell lines. For this purpose, a targeted delivery system including chitosan NPs coated with hyaluronic acid (HA-CS NPs) was created and examined in vitro. Chitosan NPs were first fabricated and loaded with TMX using the ionic-gelation method to prepare a drug-delivery system. Then, TMX-loaded CS NPs were coated by crosslinking the amino groups of chitosan to the carboxylic group of hyaluronic acid. The developed TMX delivery system was then optimized and characterized for particle fabrication, drug release, and targeting against cancer cells. The HA-CS particle size was 210 nm and its zeta potential was +25 mv. The encapsulation efficiency of TMX in NPs was 55%. TMX released from the NPs in acidic pH (5-6) was higher than the physiological pH (7.4). The cytotoxic effect of TMX-loaded HA-CS NPs on MCF7 and TMX-resistant MCF7 cells was significantly higher than TMX-loaded CS NPs and free drug. The findings confirmed the significant suppressive impact of TMX-loaded HA-CS NPs on MCF7 and TMX-resistant MCF7 cancer cells compared to the TMX-loaded CS NPs and free TMX. Graphical abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.